Skip to content
Use caution Drug recall · FDA · Published December 23, 2020

Fresenius Kabi Ketorolac Injection Recall: Particulate Matter Risk

Fresenius Kabi recalls Ketorolac injection vials due to particulate matter found in some samples. This may cause serious injury if injected. Check your vial's lot number and contact the company for details.

🇺🇸 FDA recall #D-0245-2021DrugFresenius Kabi ›
Take action

Contact the company

Recalling firmFresenius Kabi USA, LLC3 Corporate Dr · Lake Zurich, IL 60047-8930
✎ GovInfoNow plain-language explainer

Fresenius Kabi is recalling Ketorolac injection vials that may contain particulate matter. This could cause serious injury if injected into the body. Affected vials have a specific lot number and packaging. Read more at govinfonow.com/recall/36568-fresenius-kabi-ketorolac-injection-recall-particulate-matter-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/36568-fresenius-kabi-ketorolac-injection-recall-particulate-matter-risk · Updated October 4, 2026 · FDA enforcement record: FDA #D-0245-2021

Cite this page

“Fresenius Kabi Ketorolac Injection Recall: Particulate Matter Risk.” GovInfoNow, updated October 4, 2026. https://govinfonow.com/recall/36568-fresenius-kabi-ketorolac-injection-recall-particulate-matter-risk. Based on FDA recall #D-0245-2021 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0245-2021%22&limit=1).

The FDA announced on December 23, 2020, that Fresenius Kabi USA, LLC voluntarily recalled Ketorolac Tromethamine Injection due to the presence of particulate matter in reserve sample vials. The recall affects 945,425 vials distributed nationwide and in Puerto Rico.

How to tell if you have it

  • Brand: Fresenius Kabi
  • Product: Ketorolac Tromethamine Injection, USP, 30 mg per mL, packaged in 1 mL Single Dose Vials (NDC 63323-162-00); 25 x 1 mL Single Dose Vials per tray (NDC 63323-162-01)
  • Lot #: 6121083
  • Expiration: 2/2021
  • Quantity: 945,425 vials

The hazard

The recall was initiated because particulate matter was found in reserve sample vials of the drug. The FDA classified this as a Class I recall, indicating a high risk of serious adverse health consequences or death.

Context

GovInfoNow's records show Fresenius Kabi USA, LLC has had 65 other recalls on record since September 27, 2012. Recent similar recalls include a Tyenne Injection recall for glass particles on August 10, 2026, and an Xylocaine 1% Injection recall for hair particulate matter on July 16, 2026. Other recent recalls of similar products include a Ketamine HCl Injection recall for lack of sterility assurance on February 5, 2026, a Lactated Ringer's Injection recall for particulate matter on April 28, 2026, and a Papaverine HCl Injection recall for particulate matter on July 24, 2026.

How to tell if you have this one

Check for vials labeled 'Ketorolac Tromethamine Injection, USP, 30 mg per mL' with NDC 63323-162-00 or 63323-162-01. The lot number is 6121083 with an expiration date of February 2021.

  • Brand
    Fresenius Kabi
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Vial Lot Number

    Look for lot number 6121083 on the vial label. This is the specific batch affected by the particulate matter issue.

  2. Contact Manufacturer

    Reach out to Fresenius Kabi at Lake Zurich, IL 60047 for further assistance or to report concerns about the vial.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFLPuerto Rico: yesPR

FDA distribution: “Nationwide USA and Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 2.5 years after the firm started it.

1. Firm started the recall: Dec 23, 202012. FDA classified it Class I: Jan 27, 202123. Published in FDA’s Enforcement Report: Feb 3, 202134. FDA terminated the recall: Jun 9, 2023420202023
  1. Firm started the recall
  2. FDA classified it Class I
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0245-2021 (December 23, 2020) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0245-2021 to see it in context.
  • Plain-language summary written by qwen3:4b on October 4, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA